Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas

Anticancer Research

Volumn 24, Issue 3 A, 2004, Pages 1327-1335

  Li, Qian ^a   Verschraegen, Claire F ^b   Mendoza, John ^c   Hassan, Raffit ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Stehlin Found for Cancer Research   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotoxin; Mesothelin; Peritoneal mesothelioma; SS1(dsFv)PE38

Indexed keywords

CELL SURFACE PROTEIN; IMMUNOTOXIN; IMMUNOTOXIN SS1(DSFV)PE38; MESOTHELIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY K1; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MALE; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; UNITED STATES;

ANTIBODIES, MONOCLONAL; ASCITES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOTOXINS; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; PERITONEAL NEOPLASMS;

EID: 3242689904     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Antman KH, Pass HI and Schiff P: Management of mesothelioma in cancer. In: Principles and Practice of Oncology, 6th edition. (DeVita VT, Hellman S and Rosenberg SA eds) Philadelphia: Lippincott, Williams & Wilkins. 2001, pp 1943-1969.
2. Connelly RR, Spirtas R, Myers MH, Percy CL and Fraumeni JF Jr: Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 78: 1053-1060, 1987.
3. Asensio JA, Goldblatt P and Thomford NR: Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature. Arch Surg 125: 477-481, 1990.
4. van Gelder T, Hoogsteden HC, Versnel MA, deBeer PH, Vandenbroucke JP and Planteydt HT: Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 43: 222-227, 1989.
5. Kerrigan SA, Turnnir RT, Clement PB, Young RH and Churg A: Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 94: 378-385, 2002.
6. Eltabbakh GH, Piver MS, Hempling RE, Recio FO and Intengen ME: Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol 70: 6-12, 1999.
7. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G and Corson J: Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 6: 147-153, 1988.
8. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P and Yoo D: Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Sem Oncol 29: 51-61, 2002.
9. Park BJ, Alexander RH, Libutti SK, Wu P, Royalty D, Kranda KC and Bartlett DL: Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6: 582-590, 1999.
10. Nowak AK, Lake RA, Kindler HL and Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29: 82-96, 2002.
11. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL and Freedman RS: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8: 3686-3695, 2002.
12. Scheinberg DA, Sgouros G and Junghans RP: Antibody-based immunotherapies for cancer. In: Cancer Chemotherapy & Biotherapy: Principles and Practice, 3rd edition (Chabner BA and Longo DL eds.) Philadelphia: Lippincott, Williams & Wilkins. 2001, pp 850-890.
13. Chang K and Pastan I: Molecular cloning of mesothelin, a differentation antigen present on mesotheliomas and ovarian cancers. Proc Natl Acad Sci 93: 136-140, 1996.
14. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I and Willingham MC: Monoclonal antibody K1 reacts with epithelial mesotheliomas but not with lung adenocarcinoma. Am J Surg Pathol 16: 259-268, 1992.
15. Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197, 2003.
16. Chang K, Pastan I and Willingham MC: Isolation and characterization of a monoclonal antibody K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381, 1992.
17. Chang K, Pastan I and Willingham MC: Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int J Cancer 51: 548-554, 1992.
18. Argani P, Donahue-Iacobuzio C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE and Hruban RH: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868, 2001.
19. Hassan R, Viner J, Wang QC, Margulies I, Kreitman RJ and Pastan I: Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell surface antigen overexpressed in ovarian cancer and malignant mesotheliomas. J Immunother 23: 473-479, 2000.
20. Chowdhury PS, Viner JL, Beers R and Pastan I: Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci 95: 669-674, 1998.
21. Chowdhury PS and Pastan I: Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotech 17: 568-572, 1999.
22. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC and Pastan I: Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 8: 3520-3526, 2002.
23. 111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 80: 559-563, 1999.
24. Kreitman R, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ and Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247, 2001.
25. Fan D, Yano S, Shinohara H, Solorzano C, VanArsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I and Fidler IJ: Targeted therapy against human lung cancer in nude mice by high affinity recombinant antimesothelia single-chain Fv immunotoxin. Mol Cancer Ther 1: 595-600, 2002.
26. Kreitman R, Squires D, O'Hagan D, Strauss L, Fleming C, Willingham M and Pastan I: SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I study of continuous infusion. Proc Am Soc Clin Oncol 21: B22, 2002.
27. Hassan R, Kreitman R, Strauss L, Fleming C, Gupta M, Willingham M and Pastan I: SS1(dsFv)PE38 anti-mesothelin immunotoxin in advanced malignancies: Phase I and pharmacokinetic study of alternate-day infusion. Proc Am Soc Clin Oncol 21: A29, 2002.
28. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE and Hellstrom I: Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci 96: 11531-11536, 1999.
29. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE and Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616, 2003.